Gyula Ostoros

14.2k total citations · 2 hit papers
62 papers, 2.2k citations indexed

About

Gyula Ostoros is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gyula Ostoros has authored 62 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 40 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Gyula Ostoros's work include Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (11 papers). Gyula Ostoros is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (11 papers). Gyula Ostoros collaborates with scholars based in Hungary, Austria and United States. Gyula Ostoros's co-authors include Balázs Döme, Tudor–Eliade Ciuleanu, Tsveta Milenkova, Manuel Cobo, Alan Webster, József Tı́már, József Tóvári, R. McCormack, F Rényi-Vámos and Sándor Paku and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Gyula Ostoros

60 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

2023 179 citations Gyula Ostoros, Konrad Höetzenecker et al. profile →
LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2

2024 37 citations Gyula Ostoros, Ahmet Demirkazık et al. profile →

Peers

Gyula Ostoros

ONCOL

PRM

SURGE

G. Deplanque France

G. R. Hudes United States

Ann M. Mauer United States

Rupal S. Bhatt United States

Giulio Metro Italy

D. J. Richel Netherlands

Luigi Formisano Italy

Mariacarmela Santarpía Italy

Jin‐Hyoung Kang South Korea

Teresa Morán Spain

G. Deplanque France

Gyula Ostoros

1.3k ×1.1

ONCOL

812 ×0.7

PRM

633 ×0.8

542 ×0.8

225 ×1.1

SURGE

Citations per year, relative to Gyula Ostoros Gyula Ostoros (= 1×) peers G. Deplanque

Countries citing papers authored by Gyula Ostoros

Since Specialization

Citations

This map shows the geographic impact of Gyula Ostoros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gyula Ostoros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gyula Ostoros more than expected).

Fields of papers citing papers by Gyula Ostoros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gyula Ostoros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gyula Ostoros. The network helps show where Gyula Ostoros may publish in the future.

Co-authorship network of co-authors of Gyula Ostoros

This figure shows the co-authorship network connecting the top 25 collaborators of Gyula Ostoros. A scholar is included among the top collaborators of Gyula Ostoros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gyula Ostoros. Gyula Ostoros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garassino, Marina Chiara, Willemijn S.M.E. Theelen, Robert M. Jotte, et al.. (2023). LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Annals of Oncology. 34. S1309–S1310. 37 indexed citations

Bogos, Krisztina, Zoltán Kiss, Lilla Tamási, et al.. (2021). Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016. Pathology & Oncology Research. 27. 603937–603937. 9 indexed citations

Thatcher, Nicholas, Jerome H. Goldschmidt, Michael Thomas, et al.. (2019). Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. Clinical Cancer Research. 25(7). 2088–2095. 43 indexed citations

Bogos, Krisztina, Zoltán Kiss, Gabriella Gálffy, et al.. (2019). Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary. Frontiers in Oncology. 9. 1051–1051. 18 indexed citations

Sárosi, Veronika, Iveta Kudaba, Gabriella Gálffy, et al.. (2018). Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial. BMC Cancer. 18(1). 598–598. 18 indexed citations

Owonikoko, Taofeek K., Kristiaan Nackaerts, Tibor Csőszi, et al.. (2017). OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 12(1). S261–S262. 17 indexed citations

Thatcher, Nick, Michael Thomas, Gyula Ostoros, et al.. (2017). P2.03a-025 Randomized, Double-Blind, Phase 3 Study Comparing Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non-Squamous NSCLC. Journal of Thoracic Oncology. 12(1). S902–S903. 2 indexed citations

Horváth, Zsolt, László Gráf, Gabriella Gálffy, et al.. (2016). Serum Heat Shock Protein 70, as a Potential Biomarker for Small Cell Lung Cancer. Pathology & Oncology Research. 23(2). 377–383. 16 indexed citations

Nackaerts, K., Tibor Csőszi, Gyula Ostoros, et al.. (2016). Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC). Annals of Oncology. 27. vi493–vi493. 11 indexed citations

10.

Ryška, Aleš, Rafał Dziadziuszko, Büğe Öz, et al.. (2015). [Molecular diagnostics of lung cancer].. PubMed. 59(3). 259–66. 2 indexed citations

11.

Lohinai, Zoltán, Mir Alireza Hoda, Katalin Fábián, et al.. (2015). Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. Journal of Thoracic Oncology. 10(5). 738–746. 62 indexed citations

12.

Douillard, Jean‐Yves, Gyula Ostoros, Manuel Cobo, et al.. (2014). Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status. Journal of Thoracic Oncology. 9(9). 1345–1353. 348 indexed citations

13.

Cserepes, Mihály, Gyula Ostoros, Zoltán Lohinai, et al.. (2014). Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. European Journal of Cancer. 50(10). 1819–1828. 63 indexed citations

14.

Bittner, Nóra, Gyula Ostoros, & Lajos Géczi. (2013). New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background. Pathology & Oncology Research. 20(1). 11–25. 37 indexed citations

15.

Zimmermann, Matthias, Stefanie Nickl, Christopher Lambers, et al.. (2012). Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: A multi-institutional case–control study. Clinica Chimica Acta. 413(13-14). 1115–1120. 47 indexed citations

16.

Berta, Judit, István Kenessey, Judit Dobos, et al.. (2010). Apelin Expression in Human Non-small Cell Lung Cancer: Role in Angiogenesis and Prognosis. Journal of Thoracic Oncology. 5(8). 1120–1129. 106 indexed citations

17.

Amir, Eitan, Fiona Blackhall, Nick Thatcher, et al.. (2009). Antivascular agents for non-small-cell lung cancer: current status and future directions. Expert Opinion on Investigational Drugs. 18(11). 1667–1686. 5 indexed citations

18.

Döme, Balázs, Judit Dobos, József Tóvári, et al.. (2007). Circulating bone marrow‐derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry Part A. 73A(3). 186–193. 51 indexed citations

19.

Ostoros, Gyula, et al.. (2006). Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. International Journal of Gynecological Cancer. 16(S1). 391–393. 26 indexed citations

20.

Ostoros, Gyula, et al.. (1998). [Reflections on screening tests for lung cancer].. PubMed. 139(42). 2491–4. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact